Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

alimera sciences europe limited, - fluocinolone acetonide - intravitreal implant in applicator - 190 microgram(s) - fluocinolone acetonide

Մալթա - անգլերեն - Medicines Authority

boston biopharma limited malta life sciences park, building 2, level 0, san gwann sgn 3000, malta - imatinib mesilate - hard capsule - imatinib mesilate 100 mg - antineoplastic agents

Մալթա - անգլերեն - Medicines Authority

boston biopharma limited malta life sciences park, building 2, level 0, san gwann sgn 3000, malta - imatinib mesilate - hard capsule - imatinib mesilate 200 mg - antineoplastic agents

Մալթա - անգլերեն - Medicines Authority

boston biopharma limited malta life sciences park, building 2, level 0, san gwann sgn 3000, malta - imatinib - hard capsule - imatinib 400 mg - antineoplastic agents

Կանադա - անգլերեն - Health Canada

elvium life sciences - timolol (timolol maleate); dorzolamide (dorzolamide hydrochloride) - solution - 5mg; 20mg - timolol (timolol maleate) 5mg; dorzolamide (dorzolamide hydrochloride) 20mg - beta-adrenergic agents

Կանադա - անգլերեն - Health Canada

elvium life sciences - dorzolamide (dorzolamide hydrochloride); timolol (timolol maleate) - solution - 20mg; 5mg - dorzolamide (dorzolamide hydrochloride) 20mg; timolol (timolol maleate) 5mg - beta-adrenergic agents

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

protein sciences corporation - influenza a virus a/michigan/45/2015 (h1n1) recombinant hemagglutinin antigen (unii: 69h0yj871t) (influenza a virus a/michigan/45/2015 (h1n1) recombinant hemagglutinin antigen - unii:69h0yj871t) - influenza a virus a/michigan/45/2015 (h1n1) recombinant hemagglutinin antigen 45 ug in 0.5 ml

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

zydus lifesciences limited - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl) - potassium citrate 5 meq - potassium citrate is indicated for the management of renal tubular acidosis [see clinical studies (14.1)]. potassium citrate is indicated for the management of hypocitraturic calcium oxalate nephrolithiasis [see clinical studies (14.2)]. potassium citrate is indicated for the management of uric acid lithiasis with or without calcium stones [see clinical studies (14.3)]. potassium citrate extended-release tablets are contraindicated: - in patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). - in patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tr

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

protein sciences corporation - influenza a virus a/california/7/2009 (h1n1) recombinant hemagglutinin antigen (unii: 1se9z7d2qr) (influenza a virus a/california/7/2009 (h1n1) recombinant hemagglutinin antigen - unii:1se9z7d2qr), influenza a virus a/victoria/361/2011 (h3n2) recombinant hemagglutinin antigen (unii: k5313h4vgs) (influenza a virus a/victoria/361/2011 (h3n2) recombinant hemagglutinin antigen - unii:k5313h4vgs), influenza b virus b/wisconsin/1/2010 recombinant hemagglutinin antigen (unii: n9c76986u2) (influenza b virus b/wisco - influenza a virus a/california/7/2009 (h1n1) recombinant hemagglutinin antigen 45 ug in 0.5 ml - flublok is a vaccine indicated for active immunization against disease caused by influenza virus subtypes a and type b contained in the vaccine. flublok is approved for use in persons 18 through 49 years of age. flublok is contraindicated in individuals with known severe allergic reactions (e.g., anaphylaxis), to any component of the vaccine (see description [11]).  reproduction studies have been performed in rats at a dose approximately 300 times the human dose (on a mg/kg basis) and have revealed no evidence of impaired fertility or harm to the fetus due to flublok. there are, however, no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, this vaccine should be used during pregnancy only if clearly needed. the effect of flublok on embryo-fetal and pre-weaning development was evaluated in pregnant rats. animals were administered flublok by intramuscular injection twice prior to gestation and once during the period of organ

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

protein sciences corporation - influenza a virus a/california/7/2009 (h1n1) recombinant hemagglutinin antigen (unii: 1se9z7d2qr) (influenza a virus a/california/7/2009 (h1n1) recombinant hemagglutinin antigen - unii:1se9z7d2qr), influenza a virus a/texas/50/2012 (h3n2) recombinant hemagglutinin antigen (unii: 1iqz1wce3y) (influenza a virus a/texas/50/2012 (h3n2) recombinant hemagglutinin antigen - unii:1iqz1wce3y), influenza b virus b/massachusetts/2/2012 recombinant hemagglutinin antigen (unii: ayr0wzx7jh) (influenza b virus b/massachus - flublok is a vaccine indicated for active immunization against disease caused by influenza virus subtypes a and type b contained in the vaccine. flublok is approved for use in persons 18 through 49 years of age. flublok is contraindicated in individuals with known severe allergic reactions (e.g., anaphylaxis), to any component of the vaccine (see description [11]).  reproduction studies have been performed in rats at a dose approximately 300 times the human dose (on a mg/kg basis) and have revealed no evidence of impaired fertility or harm to the fetus due to flublok. there are, however, no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, this vaccine should be used during pregnancy only if clearly needed. the effect of flublok on embryo-fetal and pre-weaning development was evaluated in pregnant rats. animals were administered flublok by intramuscular injection twice prior to gestation and once during the period of organ